JHC
ORKA

Jones Hill Capital’s Oruka Therapeutics ORKA Stock Holding History

Jones Hill Capital’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-140,843
Closed -$6.91M – 40
2026
Q1 		$6.91M Buy
+140,843
New +$4.89M 1.48% 16

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jones Hill Capital's ORKA Position: Q2 2026 in Review

Jones Hill Capital sold out of Oruka Therapeutics (ORKA) in Q2 2026, closing a stake of 140,843 shares — an estimated $6.91M sold.

Jones Hill Capital first reported a position in ORKA in Q1 2026 and held it in 1 quarter. The position peaked at $6.91M in Q1 2026. 254 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Jones Hill Capital reported no remaining Oruka Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jones Hill Capital sold 140,843 Oruka Therapeutics shares in Q2 2026, an estimated $6.91M.
  • Jones Hill Capital first reported a position in Oruka Therapeutics in Q1 2026 and held it in 1 quarter.
  • Jones Hill Capital's Oruka Therapeutics position peaked at $6.91M in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Jones Hill Capital's 13F filing for Q2 2026, filed 13 Aug 2026.